LB-100
- Generic Name
- LB-100
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H20N2O4
- CAS Number
- 1632032-53-1
- Unique Ingredient Identifier
- 0C1JUU9S0L
- Background
LB-100 is under investigation in clinical trial NCT03886662 (A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)).
- Associated Conditions
- -
- Associated Therapies
- -
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering
LIXTE Biotechnology Holdings, Inc. announced a $5.8 million registered direct offering of 2,900,000 shares at $2.00 each, expected to close around April 14, 2022. Proceeds will fund working capital and development of LB-100, a novel cancer treatment compound. WestPark Capital, Inc. and WallachBeth Capital, LLC are co-placement agents.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath